Zacks Research Forecasts Higher Earnings for Gilead Sciences

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities research analysts at Zacks Research boosted their FY2025 EPS estimates for Gilead Sciences in a research report issued to clients and investors on Monday, December 9th. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will post earnings of $7.03 per share for the year, up from their prior estimate of $6.91. The consensus estimate for Gilead Sciences’ current full-year earnings is $4.37 per share. Zacks Research also issued estimates for Gilead Sciences’ Q4 2025 earnings at $1.81 EPS and FY2026 earnings at $7.50 EPS.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the previous year, the business earned $2.29 earnings per share. The firm’s quarterly revenue was up 7.0% on a year-over-year basis.

GILD has been the topic of a number of other research reports. Wolfe Research began coverage on Gilead Sciences in a report on Friday, November 15th. They issued an “outperform” rating and a $110.00 target price on the stock. Sanford C. Bernstein started coverage on Gilead Sciences in a research note on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target on the stock. Barclays boosted their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 7th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday. Finally, Piper Sandler boosted their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Twelve equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.43.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $92.38 on Thursday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The company has a market capitalization of $115.13 billion, a price-to-earnings ratio of 1,026.44, a PEG ratio of 2.86 and a beta of 0.18. The firm’s 50-day moving average price is $89.65 and its two-hundred day moving average price is $79.17. Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $98.90.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.33%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. This represents a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 447,234 shares of company stock valued at $41,288,086. 0.16% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Brass Tax Wealth Management Inc. bought a new stake in Gilead Sciences during the third quarter valued at $242,000. Garden State Investment Advisory Services LLC bought a new stake in Gilead Sciences in the third quarter valued at approximately $221,000. Franklin Resources Inc. grew its holdings in Gilead Sciences by 22.8% in the 3rd quarter. Franklin Resources Inc. now owns 2,241,354 shares of the biopharmaceutical company’s stock worth $190,611,000 after acquiring an additional 416,379 shares during the last quarter. Tri Ri Asset Management Corp bought a new stake in shares of Gilead Sciences in the third quarter worth about $3,380,000. Finally, Synovus Financial Corp raised its holdings in shares of Gilead Sciences by 99.6% during the third quarter. Synovus Financial Corp now owns 37,265 shares of the biopharmaceutical company’s stock valued at $3,124,000 after acquiring an additional 18,592 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.